Comparing GLP-1 Drugs: Why Ozempic Remains the Top Choice in 2024
The Evolving Landscape of GLP-1 Receptor Agonists: A Strategic Perspective In the rapidly advancing field of metabolic therapeutics, GLP-1 receptor agonists have revolutionized weight management and type 2 diabetes treatment. Among these, Ozempic (semaglutide) remains a dominant force in 2024, underpinned by robust clinical evidence and strategic positioning. As experts analyze the competitive landscape, understanding … Read more